Table 3.
Medicare allowed costs during follow-up – participants and controls matched for mortality
| N | Total cost | RX cost (% total) | IP cost (% total) | OP cost (% total) | Savings, 95% CI, p-value | |||
|---|---|---|---|---|---|---|---|---|
| 12 months | Alive | HBPC | 176 | $28,373 | $5394 (19.01%) | $9272 (32.68%) | $7041 (24.82%) | ($5866) ($10,606), ($1125) p = 0.015 |
| Ctrl | 176 | $22,507 | $4833 (21.69%) | $8358 (37.13%) | $3960 (17.59%) | |||
| Dead | HBPC | 20 | $21,273 | $1847 (8.68%) | $10,138 (47.66%) | $5373 (25.25%) | $37,037 $11,552, $62,522 p = 0.006 |
|
| Ctrl | 20 | $58,310 | $4174 (7.16%) | $38,119 (65.37%) | $4253 (7.29%) | |||
| 24 months | Alive | HBPC | 161 | $41,716 | $6219 (14.91%) | $13,381 (32.08%) | $12,398 (29.72%) | $726 ($6464), $7916 p = 0.84 |
| Ctrl | 161 | $42,442 | $8832 (20.81%) | $14,193 (33.44%) | $8815 (20.77%) | |||
| Dead | HBPC | 31 | $28,116 | $2154 (7.66%) | $12,516 (44.51%) | $7907 (28.12%) | $27,610 $8077, $47,142 p = 0.007 |
|
| Ctrl | 31 | $55,726 | $4214 (7.56%) | $30,732 (55.14%) | $8800 (15.79%) |
Table 3 provides patterns of medical costs and savings for matched (conditional on mortality status) HBPC participant and control samples at 12 and 24 months. HBPC participants show substantial savings at end of life relative to controls, driven strongly by reductions in in-patient costs. Prior to end of life, HBPC participants are more expensive initially, and cost neutral after the first 12 months of enrollment